Patent ruling on Lilly's Alimta lung-cancer drug expected in 2014

(Reuters) - A high-stakes decision on whether to extend U.S. marketing exclusivity of Eli Lilly and Co's blockbuster Alimta lung cancer drug is not expected until next year, following a two-week trial in Indianapolis federal court. Most industry analysts have long assumed the $2.6 billion-a-year drug will lose U.S. patent protection and face competition from cheaper generics in January 2017, with the lapse of the basic patent on the pill's chemical structure. But Lilly argued during the trial before U.S. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/patent-ruling-lillys-alimta-lung-cancer-drug-expected-192513928--finance.html